Manufacturing & Supply Chain

GSK plc has completed the demerger of its Consumer Healthcare business to form the Haleon Group. Following the Demerger, GSK is now focused purely on biopharmaceuticals, prioritising investment towards the development of innovative vaccines and specialty medicines.

Its R&D approach will continue to focus on the science of the immune system, use of human genetics and advanced technologies. Over the next five-year period, GSK expects to deliver compound annual growth in sales and adjusted operating profit of more than 5 per cent. and more than 10 per cent., respectively, at constant exchange rates (with 2021 as the base year).

Haleon is a new, world-leader in consumer healthcare with a clear strategy to outperform and run a responsible business. Haleon’s product portfolio is split among five categories: Oral Health, Pain Relief, VMS, Respiratory Health, Digestive Health and Other. Haleon’s largest category by revenue is Oral Health, which accounted for 28.5% of Haleon’s revenue in the year ended 31 December 2021. The Pain Relief and Digestive Health and Other categories also significantly contribute to revenue, respectively contributing 23.4% and 20.4% of revenue in the year ended 31 December 2021. VMS and Respiratory Health respectively accounted for 15.7% and 11.9% of revenue in the year ended 31 December 2021.